Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Former FDA commissioner Hayes dies: Arthur Hull Hayes Jr., who led FDA from April 1981 through September 1983 and was a nationally known professor of clinical pharmacology, died on Feb. 11, 2010, from complications caused by a chronic illness, according to an obituary published by Munson-Lovetere Funeral Homes. He was 76. After being appointed FDA commissioner by President Ronald Reagan, Hayes' directed FDA's response to the Tylenol tampering in 1982, called for a voluntary moratorium on direct-to-consumer advertising of prescription medicines and weathered criticism on the FDA's approval of the sweetener aspartame. He earned a Rhodes Scholar degree in philosophy, politics and economics in 1957 before studying medicine, serving in Army Medical Corps from 1965-1967 and teaching medicine and pharmacy at Cornell and Pennsylvania State University before moving to FDA, and later was provost and dean at New York Medical College. According to FDA's Web site, in 1986 Hayes shifted to executive positions in the pharmaceutical industry, served on the editorial boards of Clinical Pharmacology and Therapeutics, Rational Drug Therapy and the Journal of Clinical Pharmacology, and was president of the American Society of Clinical Pharmacology and Therapeutics and the U.S. Pharmacopoeia. He retired in 2005, five years after founding MediScience Associates consultants, part of Nelson Communications Inc

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel